Illumination for photodynamic therapy
The photodynamic therapy illumination system addresses pain and efficacy issues in PDT by varying radiation intensity through multiple modes, ensuring effective treatment with reduced discomfort.
Patent Information
- Application Number
- JP2024142021
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Photodynamic therapy (PDT) is limited by patient discomfort during treatment, which often leads to incomplete treatment sessions and reduced utilization due to severe pain, and there is a need to enhance therapeutic efficacy while minimizing pain.
A photodynamic therapy illumination system with an electronic control unit that varies the intensity of electromagnetic radiation using multiple modes: continuous increase, constant intensity, and alternating light and dark periods to manage pain and optimize treatment effectiveness.
The system reduces perceived pain and enhances PDT efficacy by minimizing photobleaching and oxygen depletion, allowing for effective treatment sessions without intolerable discomfort.
Smart Images

Figure 2024164165000001_ABST
Abstract
Description
[Technical field]
[0001] The present disclosure relates to a photodynamic therapy illumination system that includes an illumination source configured to emit electromagnetic radiation to illuminate a target surface during operation, and an electronic control unit.
[0002] The present disclosure also relates to a method for operating an illumination source, a computer program product, such as a data carrier, a kit for treating a disorder and a method for treating a skin disorder. [Background technology]
[0003] Photodynamic therapy (PDT) has been widely studied and several approaches have been successfully used in treatment. In general, there are three prerequisites for PDT: a photosensitizer, molecular oxygen and light of a specific wavelength. For dermatological PDT, a prodrug, such as aminolevulinic acid (ALA), is usually administered topically to the skin. Subsequently, the prodrug is then converted by cells, such as neoplastic cells, into the actual photosensitizer. The molecular mechanism of action in PDT is based on cellular ALA uptake, synthesis and accumulation of the photosensitizer, which can be excited by light of a specific wavelength in the presence of oxygen, leading to the formation of reactive oxygen species (ROS). ROS initiates cell death, for example in the form of apoptosis, necrosis and autophagy.
[0004] However, one of the main problems that prevent PDT from being widely accepted by patients is the considerable amount of pain that patients experience during irradiation, ranging from mild inconvenience to severe pain, to the point where treatment has to be discontinued. Furthermore, although PDT is a very effective treatment, recurrence of some diseases, such as actinic keratosis, is commonplace, and thus patients often develop other lesions in other skin areas at a later time after successful treatment, again requiring medical intervention. Moreover, some patients are not completely cured after a single PDT session and require a second session. If patients experience a very painful first PDT, they are unlikely to start or complete a second PDT, despite the fact that PDT offers superior efficacy compared to other therapeutic options. As a result, many patients are less likely to undergo treatment or retreatment. This, of course, has a significant negative impact on each individual PDT and on PDT as a whole.
[0005] As a result, pain relief, overall, is of great importance to increasing the acceptance level of PDT treatment and thus increasing utilization of this excellent treatment.
[0006] Nevertheless, PDT efficacy is also limited by some of the factors involved, namely, photosensitizer, oxygen, and light. Reduced utilization of some of these factors may hinder ROS formation. Optimized dosage forms, pretreatments, and incubation modalities can ensure adequate and abundant deposition of the photosensitizer. Furthermore, light must reach the molecules in sufficient quantities, and oxygen must be present as an energy acceptor.
[0007] In particular, the light of the illumination of the appropriate wavelength that activates each photosensitizer must be available in sufficient dose. For topical administration, a frequently used photosensitizer is protoporphyrin IX (PpIX), which is mostly produced in skin cells by administration of a precursor molecule such as ALA. PpIX is activated by a variety of different wavelengths of light, with red (approximately 635 nm), blue (approximately 420 nm), yellow (approximately 542 nm) or green (approximately 506 nm) light being most frequently used. In general, the light dose received by the target, e.g., the skin to be treated, depends on three main factors: the irradiance provided by the light source, the distance between the target area and the light source, and the duration of the irradiation. Summary of the Invention [Problem to be solved by the invention]
[0008] Current practice is to apply the entire light dose in a short interval (e.g., in the range of 7-12 min for red light or 15-20 min for blue light). This approach usually limits the occurrence of pain. And photobleaching of the photosensitizer would occur to a greater extent at higher light intensities, limiting the therapeutic effect. Photobleaching describes the effect whereby the photosensitizer is inactivated by permanent destruction of its chemical structure, e.g., by cleavage of covalent bonds. This photobleaching effect would occur simultaneously with a temporary oxygen depletion of the target tissue due to an extensive initial reaction. This causes a rapid decrease in the oxygen required for ROS formation. Any photobleaching that occurs during the oxygen-limited phase would be futile due to the low production of cytotoxic singlet oxygen.
[0009] It is noted that the above statements are not to be construed as admissions of prior art. They are made to illustrate the context of concepts disclosed herein, which may not yet be publicly available.
[0010] It is an object of the present invention to provide an improved photodynamic therapy lighting system, an improved method for operating a lighting source, an improved computer program product such as a data carrier, an improved kit for treating a disease, and / or an improved method for treating a skin disease, preferably permitted or configured to limit the pain burden while advantageously maintaining an acceptable effect of the therapy, and / or permitted or configured to enhance the effect of the therapy. [Means for solving the problem]
[0011] The respective objects will be achieved, inter alia, by the subject matter of the independent claims. Advantageous embodiments and refinements are the subject matter of the dependent claims. However, further advantageous concepts will be disclosed herein in addition to the subject matter of the present claims.
[0012] One aspect of the present disclosure relates to a photodynamic therapy illumination system, the illumination system including an illumination source configured to emit electromagnetic radiation to illuminate a target surface during operation and an electronic control unit; the illumination source is configured to vary an intensity of electromagnetic radiation emitted by the illumination source; the electronic control unit is operably coupled to the illumination sources and configured to control operation of the illumination sources in accordance with a lighting protocol during a lighting session executed with the lighting system; and The lighting protocol includes instructions for operating the lighting source during the lighting session in a number of different modes, the modes including: a) a first mode, wherein in the first mode, the electronic control unit controls operation of the illumination source to continuously or quasi-continuously increase an intensity of electromagnetic radiation emitted by the illumination source from a base intensity B to a target intensity T within a first mode time interval; b) a second mode, where in the second mode, the electronic control unit controls operation of the illumination source to cause an intensity of electromagnetic radiation emitted by the illumination source to be constant or substantially constant during a second mode time interval; and c) a third mode, wherein in the third mode, said electronic control unit controls operation of said illumination source to alternate between periods of darkness and periods of illumination during a third mode time interval. Including, wherein an intensity of electromagnetic radiation emitted by the illumination source is lower during the darkness periods than during the illumination periods, or during the darkness periods the illumination source does not emit electromagnetic radiation, while during the illumination periods the illumination source emits electromagnetic radiation. The control unit may be configured to control the operating voltage and / or the operating current supplied to the illumination source in a manner to effect operation of the illumination source as desired for each mode.
[0013] The proposed lighting system can limit or reduce the perceived pain burden. This is achieved, among other things, by operating the lighting source during the lighting session in different modes as described in more detail hereinafter. The proposed lighting system and, in particular, the lighting protocol can increase the efficacy of PDT. Thus, the proposed system and / or protocol can provide an efficient therapy while optimizing pain.
[0014] In a first mode, the intensity of the electromagnetic radiation emitted by the illumination source increases continuously or quasi-continuously from a base intensity B to a target intensity T. The term "quasi-continuously" means that the intensity of the emitted radiation is constant for a maximum duration less than or equal to one of the following values: 5 seconds, 4 seconds, 3 seconds, 2 seconds, 1 second or 500 ms. The term "continuously" means that the intensity of the emitted electromagnetic radiation is constant for a maximum duration less than or equal to one of the following values related to "quasi-continuously", preferably 400 ms, 300 ms, 200 ms, 100 ms, 50 ms, 25 ms, 20 ms, 15 ms, 10 ms, 5 ms, 4 ms, 3 ms, 2 ms, 1 ms. As characterized or determined by the electrical energy supplied to the illumination source, corresponding values would be characteristic for a continuously or quasi-continuously increasing operating voltage and / or current.
[0015] A continuous or quasi-continuous increase in intensity can trigger the onset of a mild reaction. The increase in intensity can reduce the initial photobleaching and / or promote the reoxygenation of the treated skin. Apart from that, a continuous increase in irradiance may trigger sufficient photodynamic effects, including an early inflammatory reaction that induces vasodilation for better oxygenation. Here we describe the process during PDT that leads to the destruction of cells. Hence, the efficiency of the treatment during the first mode will be guaranteed.
[0016] Another advantage of the first mode is that the continuous increase in irradiance on the skin - the irradiance on or at the skin depends on the radiation intensity as well as the distance between said illumination source and the skin - allows the application of sensory nerve endings in the skin to the stimulation, balancing the pain sensation and ultimately reducing the pain burden in the patient. A slow increase in irradiance over an interval of 4 to 10 minutes has proven acceptable.
[0017] In the second mode, the intensity of the electromagnetic radiation emitted by the illumination source is constant or substantially constant. The term "substantially constant" means that the maximum deviation from the intensity I is less than or equal to one of the following values: 15%, 10%, 5%. I is a constant intensity during the second mode. I may be equal to T.
[0018] The constant or constant intensity electromagnetic radiation in the second mode can provide a relatively high irradiance, preferably for a short period of time, which, for example, of limited duration, would assist or contribute to maintaining a sustained photodynamic effect, preferably without causing an intolerable pain burden.
[0019] In a third mode, the illumination source is operated to alternate between periods of darkness and illumination. The periods of darkness allow neuronal activation to disappear to some extent, resulting in a lower pain burden. The illumination periods can allow the achievement of a target light dose for the illumination session. In the illumination periods, the intensity is advantageously greater than in the darkness periods. In the darkness periods, the illumination source can be operated to emit a lower intensity or no radiation at all.
[0020] Moreover, another advantage of the third mode is the balance ratio between oxygen consumption and oxygen supply: the supply of oxygen during the dark period can favorably support the efficiency of the treatment by preventing late oxygen depletion.
[0021] Therefore, the combination of the first, second and third modes is - A gentle onset of response that reduces pain burden, reduces early photobleaching, and promotes reoxygenation of treated tissues; - sufficient photodynamic effect, including an early inflammatory response that induces vasodilation for better oxygenation, reoxygenation and thus further photosensitizer activation, especially in the later stages of the irradiation, for example when using higher or higher impact rates, to prevent late oxygen depletion, and - It can provide a moderate or no increase in therapy duration to achieve a given light dose on the irradiation target while maintaining an effective light dose without causing an intolerable pain burden.
[0022] In certain embodiments, B may be less than or equal to one of the following values: 0.5T, 0.45T, 0.4T, 0.35T, 0.3T. Alternatively or additionally, B may be greater than or equal to one of the following values: 0.1T, 0.15T, 0.2T, 0.25T, 0.3T. Thus, B may be between 0.1T and 0.5T, or any other range created by combining the values in the two lists.
[0023] Appropriately selecting B allows sufficient coverage for the stimulation of sensory nerve endings in the skin and can balance the pain sensation. This results in a reduced pain burden. Furthermore, sufficient photodynamic effects are achieved or promoted. For example, higher values of B, greater than 0.6T, may cause excessive initial pain during the illumination session. Values below 0.1T may be sufficient to promote substantial photodynamic effects and / or result in unstable irradiation due to technical limitations.
[0024] In an embodiment, the constant or quasi-constant intensity during the second mode will be the target intensity T in the first mode. This will allow for direct transition from the first mode to the second mode. The advantage is that once the target intensity is reached, the efficiency of the treatment is not jeopardized by changing said intensity. Furthermore, direct transition from the first to the second mode may result in less stimulation of the patient's nerves and thus a lower pain burden.
[0025] In certain embodiments, the intensity during the illumination phase will be T. This will reduce pain burden because the nerve is already applied to T, e.g., from a prior mode of the illumination protocol.
[0026] In an embodiment, the maximum intensity between the first, second and third modes will be T. This will also result in less stimulation of the patient's nerves and thus contribute to a reduced pain burden.
[0027] In one embodiment, the intensity will increase linearly in the first mode from B to T. A linear increase can be easily adjusted to the increasing rate of pain and is comfortable to the patient because the increase is predictable.
[0028] In one embodiment, the intensity will be strictly monotonically increasing in the first mode, where a step increase in intensity is more likely to be noticed by the patient than a strictly monotonically increasing intensity, which in turn is associated with reduced pain.
[0029] In certain embodiments, the intensity will increase non-linearly in the first mode, at the beginning or beginning of the first mode, and the intensity will increase more slowly later in the first mode, allowing the beneficial effects of the photodynamic effect to occur early and maintaining the initial phase of the nerve application and the intensity.
[0030] In an embodiment, the illumination protocol includes a priming mode. The priming mode is a mode of operation of the illumination source that precedes a first mode. In a priming mode of operation, the intensity of electromagnetic radiation emitted by the illumination source will be constant or substantially constant for a priming mode time interval. The intensity in the priming mode is P. P is less than or equal to a base intensity B in the first mode. A subject / patient irradiated with the protocol becomes accustomed to the irradiance during the initial operation of the illumination source in the priming mode. When the priming mode is applied, the intensity in the first mode following the priming mode increases linearly and / or at a faster rate than without the priming mode, preferably without a significant increase in perceived pain to the user.
[0031] In certain embodiments, the illumination source will be operated in a first mode before being operated in a second mode and / or before being operated in a third mode during the lighting session. The first mode allows the nerves to get used to the radiation intensity or pain burden during the lighting session. For this purpose, the first mode preferably uses an initial low intensity. In order to reduce the pain sensation, it would therefore be advantageous to perform the first mode before a further mode, for example a mode characterized by an initial light intensity of the first mode, for example B, higher.
[0032] In an embodiment, the illumination source will be operated in a second mode after the first mode and / or before the third mode during the illumination session. Since the second mode will have a constant intensity, it is advantageous for pain reduction if the second mode is preceded by the first mode which serves to habituate the nerve to the light intensity of the second mode. Furthermore, it is also convenient to have a mode of constant intensity (second mode) between the increasing intensity (first mode) and the alternating dark and light periods (third mode), since the second mode is where the pain burden is highest. The subsequent dark and light periods can make the highest pain less noticeable to the user in the middle of the light period. The user may preferably remember the moderate pain and low initial pain during the third mode.
[0033] In one embodiment, the beginning of operation of the illumination source in a first mode defines the beginning of the lighting session and the end of operation of the illumination source in a third mode defines the end of the lighting session. If the priming mode is applied, the beginning of operation of the illumination source in the priming mode defines the beginning of the lighting session.
[0034] In an embodiment, all modes selected from the first, second and third modes of operation of the illumination source occur once, preferably only once, during the illumination session, such that the total duration is kept to less than 16 minutes, which most patients and physicians would tolerate, for example, in terms of pain burden and time spent. This duration may include or exclude operation in the priming mode.
[0035] In an embodiment, the illumination system has a target position or can define a target position to position a target surface relative to the illumination source during the illumination session. The target position (i.e. the position of the target surface relative to the illumination source) is defined by a seating surface that contacts a portion of the user's head, e.g., the forehead or chin, which portion of the user's head can remain in contact with the seating surface during the entire session. The target position can be located away from a radiation exit surface of the illumination source. A gas phase medium can be present between the radiation exit surface of the illumination source, e.g., a surface of an optical element, e.g., a diffuser or lens, and the target surface and / or the target position.
[0036] As used herein, the term "target surface" refers to the surface to be illuminated by the electromagnetic radiation emitted by the illumination source.
[0037] The term "target position" refers to the position of a target surface relative to the illumination source. In other words, the target position is a position determined by the design of the illumination device. The target position is a position where an illuminated surface should be located relative to the illumination device during operation of the device, i.e. during the illumination session. For example, at the target position, the radiation generated by the illumination device has, for example, a desired irradiance distribution along the target surface. If the target surface is located at a different position relative to the illumination source, the irradiance distribution is different and / or not suitable for a desired purpose.
[0038] As used herein, the term "seating surface" refers to a surface suitable for supporting a body part of a user, such as the head, preferably at said target location during operation. The body part includes the target surface that is illuminated using said lighting device. The seating surface is formed by a mechanical support.
[0039] In an embodiment, the distance between the radiation exit surface of the illumination source and the target location may be less than or equal to any one of the following values: 20 cm, 15 cm, 10 cm, 8 cm, 7 cm, 6 cm, 5 cm. Alternatively or additionally, the distance between the radiation exit surface of the illumination source and the target location may be greater than or equal to any one of the following values: 1 cm, 2 cm, 3 cm, 4 cm, 5 cm. The distance between the radiation exit surface of the illumination source and the target location is between 1 cm and 20 cm, preferably between 5 cm and 8 cm.
[0040] PDT efficacy is potentially limited by any of the contributing factors: photosensitizer, oxygen, and light dose. In general, the light dose received by the target, e.g., treated skin, depends on three main factors. One of them is the distance between the target surface and the light source. The distance has a direct effect on the light dose received by the target, since the intensity at a particular location depends on the distance of that location from the illumination source. A distance between 1 cm and 20 cm, preferably between 5 cm and 8 cm, is advantageous, since it allows the maximum effect of PDT to be achieved. Furthermore, the perceived pain will be acceptable to patients at the above-mentioned distances, especially for typical applied irradiances.
[0041] In an embodiment, the illumination source may comprise at least one optoelectronic semiconductor chip, e.g. a light emitting diode chip, for generating electromagnetic radiation. This allows for a reliable, cost-effective and precisely packaged illumination source. The optoelectronic chip allows for the emission wavelength to be easily tuned to the required (peak) wavelength, e.g. by suitable processing of the active area of the chip, e.g. by band gap processing. Thus, electrical energy can be efficiently converted into radiant energy in the relevant wavelength range.
[0042] In an embodiment, the radiation emitted by the illumination source may be incoherent radiation, which is easier to handle compared to coherent radiation.
[0043] In an embodiment, the radiation emitted by the illumination source may be monochromatic, for example, of one particular color of light.
[0044] In certain embodiments, the electromagnetic radiation will have a peak wavelength in the visible spectral range, for example in the red, blue, green, or yellow spectral range.
[0045] In certain embodiments, the electromagnetic radiation has a peak wavelength in the red spectral range (hereinafter also referred to as "red light"). The peak wavelength of the illumination source is longer than 500 nm, longer than 600 nm, or longer than 630 nm. The peak wavelength may be shorter than 700 nm. The peak wavelength may be 635 nm. Red light has the advantage of reaching areas of the body deeper away from the skin more easily than light of a shorter wavelength, which is highly intense and absorbed more significantly in body tissue than red light. Thus, the present disclosure uses red light as an embodiment.
[0046] In an embodiment, the illumination system can be configured to illuminate a target surface with a predetermined light dose during the illumination session, the light dose being the following value when the target surface is positioned at the target position relative to the illumination source during the illumination session: 30 J / cm 2 , 35J / cm 2 , 37J / cm 2 Alternatively or additionally, the light dose may be greater than or equal to one of the following values when a target surface is positioned at the target position relative to the illumination source during the illumination session: 45 J / cm 2 , 40J / cm 2 , 37J / cm 2 The above values in particular hold at least for red light.
[0047] A sufficient light dose is one of the key requirements for successful PDT. However, when choosing the light dose, the maximum tolerable level of pain for the patient must also be taken into account. 2 In particular, the range of light doses between 37 J / cm 2 A light dose of, for example, 100 uL will be recognized as the best compromise between adequate therapeutic effect and pain burden when using red light.
[0048] In another embodiment, the electromagnetic radiation has a peak wavelength in the blue spectral range (hereinafter also referred to as "blue light"). The peak wavelength of the illumination source may be between 400 nm and 490 nm, for example 420 nm.
[0049] In an embodiment, the illumination system may be configured to illuminate the target surface with a predetermined light dose during the illumination session, the light dose being equal to or greater than 8 J / cm when the target surface is positioned at the target position relative to the illumination source during the illumination session. 2 , 9J / cm 2 , 10J / cm 2 Alternatively or additionally, the light dose may be greater than or equal to one of the following values when the target surface is positioned at the target position relative to the illumination source during the illumination session: 12 J / cm 2 , 11J / cm 2 , 10J / cm 2 The above values in particular hold at least for blue light.
[0050] 8 and 12 J / cm 2 Light doses in the range between 10 and 10 J / cm 2 would be recognized as the best compromise between adequate therapeutic effect and pain burden when using, for example, blue light.
[0051] It is noted that yellow or green light could also be used, which would be especially true if ALA is used as a prodrug, since the photosensitizer PpIX absorbs not only red and / or blue light, but also green and / or yellow light.
[0052] In an embodiment, the first mode time interval, the second mode time interval, and / or the third mode time interval may be greater than or equal to one of the following values: 1 minute, 15 minutes, 2 minutes, 2.5 minutes, 3 minutes, 3.5 minutes, 4 minutes, 4.5 minutes, 5 minutes. Alternatively or additionally, the first mode time interval, the second mode time interval, and / or the third mode time interval may be less than or equal to one of the following values: 10 minutes, 9.5 minutes, 9 minutes, 8.5 minutes, 8 minutes, 7.5 minutes, 7 minutes, 6.5 minutes, 6 minutes, 5.5 minutes, 5 minutes.
[0053] In an embodiment, the first mode time interval and / or the second mode time interval may be shorter than the third mode time interval such that the third mode will provide the greatest contribution of the total light dose delivered to the target surface during the lighting session.
[0054] In an embodiment, the priming mode time interval may be shorter than the first mode time interval, the second mode time interval, and / or the third mode time interval.
[0055] In certain embodiments, the priming mode time interval may be less than or equal to one of the following values: 4 minutes, 3 minutes, 2 minutes, 1 minute. Alternatively or additionally, the priming mode time interval may be greater than or equal to one of the following values: 10 seconds, 20 seconds, 30 seconds, 1 minute.
[0056] In an embodiment, the first mode time interval may be shorter than the second mode time interval. In this manner, the illumination duration with an intensity less than T will be kept relatively small. Thus, the session duration is not unnecessarily extended.
[0057] In certain embodiments, the first mode time interval and / or the second mode time interval may be longer than the duration of a single dark period and / or a single light period, and is preferably at least 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, where days is the duration of one single dark period and / or one single light period.
[0058] In certain embodiments, the duration of one dark period and / or one light period may be less than or equal to one of the following values: 60 seconds, 50 seconds, 45 seconds, 40 seconds, 35 seconds, 30 seconds, 25 seconds, 20 seconds. Alternatively or additionally, the duration of one dark period and / or one light period may be greater than or equal to one of the following values: 15 seconds, 20 seconds, 25 seconds, 30 seconds. Period durations in the range between 15 and 60 seconds are advantageous to take advantage of the positive effects without unnecessarily increasing the duration of the treatment.
[0059] In some embodiments, the durations of the different darkness periods in the third mode may be equal. In some embodiments, the durations of the different illumination periods in the third mode may be equal. In some embodiments, the duration of the darkness periods may be constant and may be equal or different from the duration of the illumination periods.
[0060] In an embodiment, the duration of the dark period may be less than the duration of the illumination period, resulting in shorter interruptions in illumination during the third mode, which contributes to maintaining session duration at a desired time.
[0061] In some embodiments, the duration of the second mode time interval and / or the duration of the first mode time interval and the second mode time interval together is less than or equal to one of the following values: 12 minutes, 11 minutes, 10 minutes, 9 minutes, 8 minutes. Thus, for example, the first pain relief due to the darkness period in the third mode after the second mode will occur when or before the patient experiences maximum pain. It has been reported that patients perceive maximum pain or unbearable pain, for example, after about 10 minutes during a PDT session. Therefore, it is advantageous in terms of pain management to combine the second mode or the first and second modes together and keep it to less than 10 minutes.
[0062] In certain embodiments, the duration of the entire lighting session may be less than or equal to one of the following values: 20 minutes, 19 minutes, 18 minutes, 17 minutes, 16 minutes, 15 minutes, 14 minutes, 13 minutes. Session durations of up to 20 minutes are typically well-accepted by users.
[0063] In certain embodiments, the duration of the entire lighting session may be greater than or equal to one of the following values: 10 minutes, 11 minutes, 12 minutes, 13 minutes. The duration of the session may be, for example, between 10 and 20 minutes.
[0064] In an embodiment, the intensity during each illumination period in the third mode may be the same.
[0065] In an embodiment, the intensity during the dark period may be less than or equal to B, or even equal to zero. Therefore, oxygen resupply will be promoted during the dark period.
[0066] In certain embodiments, the intensity during a single illumination period may be constant or substantially constant. A constant or substantially constant intensity during a single illumination period contributes to a more predictable photodynamic effect.
[0067] In some embodiments, the intensity may vary between different illumination phases. The different intensity variations may help to regulate the patient's pain burden or burden during treatment. For example, at the beginning of the third mode, the intensity of the illumination phase may be higher than that near the end of the third mode.
[0068] In one embodiment, the lighting protocol governs the entire lighting session.
[0069] Another aspect of the present disclosure relates to a method for operating an illumination source, wherein the illumination source is operated according to a lighting protocol during a lighting session performed, for example, in a lighting system as described above, and wherein the lighting protocol includes instructions for operating the illumination source during the lighting session in different modes as described above.
[0070] Furthermore, the present disclosure also relates to a computer program product, such as a data carrier, e.g. a non-transitory data carrier, or a data stream, which contains machine-readable instructions, in particular when loaded and / or executed by a computer system, e.g. by its electronic control unit, for operating an illumination source according to the above-mentioned protocol.
[0071] Yet another aspect relates to a kit for treating a disease, e.g., a skin disease, such as a neoplastic skin disease, comprising a pharmaceutical agent suitable for topical administration to the skin in the area to be treated and an illumination system as described above, wherein the illumination system is configured to illuminate the area of the skin to which the substance has been administered.
[0072] In certain embodiments, the pharmaceutical agent may be a photosensitizer or a precursor of such an agent that is excited by light in the emission spectrum.
[0073] In certain embodiments, the pharmaceutical agent can include 5-aminolevulinic acid, which is well studied and considered a reliable prodrug for generating photosensitizers.
[0074] Yet another aspect relates to a method for treating a skin condition comprising the steps of: applying a medicinal product to the surface of the skin in the area to be treated; illuminating the area with an illumination source according to the method as described above; and / or using the illumination system as described above.
[0075] In certain embodiments, the lighting system, the kit and / or the method can be used to treat a skin disease or disorder, which may be or include actinic keratosis, basal cell carcinoma, in situ squamous cell carcinoma, warts, acne, wound healing disorders / chronic wounds, neoplastic skin diseases such as bacterial and / or fungal infectious or inflammatory skin diseases.
[0076] It is noted that this disclosure covers non-therapeutic methods.
[0077] Due to the low pain burden, the illumination system can be universally used to treat a variety of disorders.
[0078] Of course, the features described above relating to different aspects and embodiments can be combined with each other and with the features described above. Thus, features relating to the system also apply to the method and kit and vice versa.
[0079] Further features and modifications will become apparent from the following description of exemplary embodiments taken in conjunction with the accompanying drawings. [Brief description of the drawings]
[0080] [Figure 1] FIG. 1 shows a schematic perspective view of an illumination system and a target surface. [Diagram 2] FIG. 2 shows a diagram illustrating the illumination protocol. [Diagram 3] FIG. 3 shows a diagram illustrating a variation of the illumination protocol of FIG. [Figure 4] FIG. 4 shows a diagram illustrating yet another variation of the illumination protocol of FIG. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS EXAMPLES
[0081] FIG. 1 shows, for example, an illumination system 1 for photodynamic therapy (PDT). The illumination system 1 comprises an illumination source 2 configured to emit electromagnetic radiation 3 to illuminate a target surface 4 during operation, and an electronic control unit 5. The target surface 4 may be human skin, for example the skin of the head or other area to be treated. Furthermore, PDT requires a photosensitizer and molecular oxygen (not explicitly shown). Usually, the photosensitizer is obtained by a prodrug (not explicitly shown), which is conveniently administered locally to the skin in the target area and is then converted by cells, preferably neoplastic cells, into the actual photosensitizer. The prodrug may be 5-aminolevulinic acid (5-ALA), an endogenous precursor for heme biosynthesis.
[0082] The molecular mechanism of action in PDT is based on cellular aminolevulinic acid uptake, synthesis, and accumulation of the photosensitizer, which is excited by light of specific wavelengths, leading to the formation of reactive oxygen species (ROS) in the presence of oxygen. These ROS species can initiate cell death in the form of apoptosis, necrosis, and / or autophagy.
[0083] The illumination source 2 is configured such that the intensity of the electromagnetic radiation 3 emitted by the illumination source 2 and / or that reaching the target surface 4 can be varied. Moreover, the distance between the target surface 4 and the illumination source 2 of the illumination system 1 can be adjusted and thus varied. However, it is preferred that the target surface 4 has a fixed position relative to the illumination source.
[0084] The illumination source 2 may include a light emitting diode (LED) or a number of light emitting diodes, particularly those under the trade name BF-RhodoLED. (R) Illumination sources such as those sold by Biofrontera AG at 1000 0 C. are suitable. The light emitted by light emitting diodes promotes the formation of reactive oxygen species (ROS). The wavelength of the light emitted by the illumination source may be longer than 400 nm, longer than 500 nm or longer than 600 nm. For example, the wavelength may be 635 nm, i.e. radiation in the red spectral range. As another example, the wavelength may be 420 nm, i.e. radiation in the blue spectral range. Alternatively, yellow or green radiation may be applied to activate the photosensitizer appropriately.
[0085] The illumination system 1 may have a target position or may define a target position at which the target surface 2 is located relative to the illumination source 2 during the illumination session. The target position may be defined by a support surface that contacts the user's head, e.g. the forehead or chin area. The area may remain in contact with the support surface during the entire session. The target position may be located at a distance from the radiation exit surface 2 of the illumination source. A gaseous medium may be present between the radiation exit surface 2 of the illumination source, e.g. the surface of an optical element, e.g. a diffuser or lens, and the target surface 4 and / or the target position.
[0086] The distance between the radiation exit surface 2 of the illumination source and the target position may be less than or equal to one of the following values: 20 cm, 15 cm, 10 cm, 8 cm, 7 cm, 6 cm, 5 cm. Alternatively or additionally, the distance between the radiation exit surface 2 of the illumination source and the target position may be greater than or equal to one of the following values: 1 cm, 2 cm, 3 cm, 4 cm, 5 cm. The distance between the radiation exit surface 2 of the illumination source and the target position may be between 1 cm and 20 cm, preferably between 5 cm and 8 cm.
[0087] The illumination source 2 may comprise at least one optoelectronic semiconductor chip, e.g. a light emitting diode chip, which generates the electromagnetic radiation. The radiation 2 emitted by the illumination source may be incoherent radiation. It may be, for example, a single color of light of one specific color. The electromagnetic spectrum emitted by the illumination source 2 may have a peak wavelength within the visible spectral range, e.g. the red or blue spectral range. The emission spectrum may be narrow. For example, the full width at half maximum (FWHM) of the spectrum may be less than 100 nm, e.g. 50 nm or less.
[0088] An electronic control unit 5 is operably connected to the illumination source 2 and configured to control operation of the illumination source 2 according to a lighting protocol during a lighting session executed by the lighting system 1. The electronic control unit may be part of a computer. The electronic control unit may be a CPU (Central Processing Unit) or a microcontroller. The lighting protocol includes instructions for operating the illumination source 2 during the lighting session in a number of different modes, which is disclosed in detail in FIG. 2.
[0089] FIG. 2 shows a two-axis diagram of the lighting protocol, where the first axis represents the duration of radiation treatment in seconds and the second axis represents the light intensity in percentage. The lighting protocol will govern the entire lighting session.
[0090] During a first mode a, which is executed initially when using the illumination system 1, the electronic control unit 5 controls the operation of the illumination source 2 so that the intensity of the electromagnetic radiation 3 emitted by the illumination source 2 increases continuously or quasi-continuously from a base intensity B (30%) to a target intensity T (100%) during a first mode time interval.
[0091] As illustrated in Fig. 2, a linear trend is applied, increasing the light intensity from 30% to 100% light intensity over the course of 5 or 5.5 minutes. Of course, other durations are possible. The intensity at 100% does not have to be the maximum intensity that can be emitted by the illumination source 2, but rather specifies the maximum intensity during the illumination session. Alternatively, the intensity may be increased non-linearly in a first mode a (see for example Fig. 3). Here, the slope is preferably smaller at the beginning than later, which is advantageous for sensitizing nerve endings.
[0092] The first mode a can reduce the initial photobleaching, predicting the onset of a mild reaction, and promote a slow but continuously increasing irradiance that triggers sufficient photodynamic effects, including reoxygenation of treated tissues and an early inflammatory reaction that induces vasodilation for better oxygen supply. The photodynamic effect refers to the process during PDT that leads to the destruction of cells, where photobleaching refers to the effect that the photosensitizer is inactivated by the permanent destruction of its chemical structure, for example, by the cleavage of covalent bonds. The photobleaching effect can occur with a temporary oxygen depletion in the target tissue due to the extensive initial reaction. This causes a rapid decrease in oxygen, thus limiting the formation of ROS. Furthermore, the slower onset phase allows application to the stimulation of sensory nerve endings in the skin, thereby reducing the pain perceived by the patient.
[0093] After reaching 100% light intensity, a second mode b follows, in which the electronic control unit 5 controls the operation of the illumination source 2 so that the intensity of the electromagnetic radiation 3 emitted by said illumination source is constant or substantially constant during a second mode time interval. As shown in Fig. 2, in the second mode b, the maximum light intensity of the first mode a is maintained. The light intensity can be kept constant for approximately 4.5 minutes. Of course, other durations are possible.
[0094] This second mode b is important to deliver high energy to the target in a relatively short period, thus keeping the total duration of the session well below 16 minutes, which is considered acceptable by most patients and doctors in terms of pain burden. Alternatively, the electronic control unit 5 controls the operation of the illumination source 2 to shut off the irradiance or to operate the illumination source 2 such that the intensity is reduced after 10 minutes, for example by a first darkness period in the next mode (mode c below), thereby counteracting the excessive increase in pain.
[0095] In the second mode b, the intensity of the electromagnetic radiation emitted by the illumination source is constant or substantially constant. The intensity during the second mode b may be equal to the target intensity T in the first mode.
[0096] The second mode b is then followed by a third mode c, which is the final mode of the protocol. In the third mode c, the electronic control unit 5 controls the operation of the illumination source 2 to alternate between periods of darkness and illumination over a third mode time interval, for example 6 minutes. The duration of the third mode is such that the desired light dose received at the target surface is, for example, at least 37 J / cm, which is suitable for red light in particular. 2 Or at least 10 J / cm2, which is especially suitable for blue light. 2 It can be adjusted to be.
[0097] The intensity of electromagnetic radiation 3 emitted by illumination source 2 is lower in the dark period than in the illumination period. In the illustrated example, illumination source 2 does not emit electromagnetic radiation in the dark period and illumination source 2 emits electromagnetic radiation 3 in the illumination period, where the light intensity of said illumination period is the same as the light intensity of mode 2 and the maximum light intensity of mode 1. The relative intensities can be adjusted as needed.
[0098] This alternating intensity is maintained for approximately 4 minutes or more in the third mode c. In the example shown in FIG. 3, the protocol includes 7 light periods and 7 dark periods, which in particular reduces neuronal activation to some extent and reduces pain. The duration of one of the dark periods in the third mode c is constant and equal to the duration of one of the light periods. The duration of one period is 20 seconds each. During the light periods, the light intensity is kept at 100%. After approximately 14 minutes, the illumination is completely stopped and the third mode c ends. The number of light periods and dark periods may of course vary and may be of absolute or relative duration. It is also still acceptable to operate the light source not to emit any radiation during the dark periods, but instead to a low intensity, for example up to 30% of the maximum intensity. The intensity in a single light period is constant or substantially constant.
[0099] Thanks to the alternating phase, the target tissue is subjected to a sufficient dark period, which can reduce photobleaching and / or promote reoxygenation of the treated tissue, leading to improved efficacy. Furthermore, the pause illumination of the final mode c reduces neuronal activation to some extent. Therefore, the perceived pain is significantly reduced.
[0100] This third mode c has a total light dose of approximately 37 J / cm 2 This continues until it reaches 37J / cm 2 This value holds in particular for red light at least. A light dose of approximately 37 J / cm 2 Increasing the protocol duration while maintaining the same blood flow rate is beneficial because it may ensure the most balanced ratio of oxygen consumption and delivery.
[0101] Alternatively, the third mode c has a total light dose of approximately 10 J / cm 2 This continues until it reaches 10J / cm 2 This value holds in particular for blue light at least. 2Increasing the protocol duration while maintaining the same blood flow rate is beneficial because it may ensure the most balanced ratio of oxygen consumption and delivery.
[0102] If yellow or green light is used, the total light dose targeted can be adjusted accordingly.
[0103] The duration of the entire lighting session is conveniently kept to less than 20 minutes, or even 16 minutes.
[0104] Fragmenting the illumination with intervals of darkness alternating with higher intensity light allows for reoxygenation and thus further photosensitizer activation during the later phase of illumination, especially when using high fluence rates to prevent late oxygen depletion, so that treatment times limited by pain can be used in a time-efficient manner.
[0105] The durations of the different dark periods in the third mode c are equal and / or constant, as are the durations of the different illumination periods in the third mode c. Alternatively, the durations may vary between the different dark periods and / or illumination periods. The intensity of the illumination periods may also vary, e.g., decrease towards the end of the illumination session. In some embodiments, the duration of the dark periods may be shorter than the duration of the illumination periods. This will contribute to shortening the interruption of the illumination during the third mode and to keeping the session duration at a desired time.
[0106] The beginning of the operation of the illumination source 2 in the first mode a defines the start of a lighting session, and the end of the operation of the illumination source 2 in the third mode c defines the end of the lighting session.
[0107] Figure 3 illustrates a variation of the illumination protocol shown in Figure 2. Here, in a first mode of operation (mode a), initially the intensity increases non-linearly, slower than later. In an interval a1, the increase may be non-linear, and in the following interval a2, it may be linear. The (constant) slope in the linear section may be greater than or equal to all the slopes of the non-linear sections. From mode b, the protocol may continue, for example, as depicted in Figure 2.
[0108] Figure 4 illustrates another variation of the illumination protocol shown in Figure 2, where a priming mode p is included before mode a is initiated. The duration of the priming mode is 3 minutes or less. The intensity during the priming mode may be equal to intensity B discussed in Figure 2. In the specific example of Figures 3 and 4, the initiation of the second mode (mode b) is only shown as an example at about 340 seconds.
[0109] The duration of the total lighting session may be less than or equal to one of the following values: 20 minutes, 19 minutes, 18 minutes, 17 minutes, 16 minutes, 15 minutes, 14 minutes, 13 minutes. The first mode time interval and / or the second mode time interval may be shorter than the third mode time interval. The first mode time interval may be shorter or longer than the second mode time interval.
[0110] Above, several durations have been specified for the modes. However, for each mode - the first mode, the second mode and / or the third mode - a time interval greater than or equal to one of the following values may be applied: 1 minute, 15 minutes, 2 minutes, 2.5 minutes, 3 minutes, 3.5 minutes, 4 minutes, 4.5 minutes, 5 minutes. Alternatively or additionally, for each mode a time interval less than or equal to one of the following values may be applied: 10 minutes, 9.5 minutes, 9 minutes, 8.5 minutes, 8 minutes, 7.5 minutes, 7 minutes, 6.5 minutes, 6 minutes, 5.5 minutes, 5 minutes. In this way, the lighting protocol can be adjusted, for example, to different situations.
[0111] The present disclosure also provides a computer program product, such as a data carrier, e.g. a non-transitory data carrier, or a data stream, which may in particular contain machine-readable instructions which, when loaded into a computer system and / or executed by the computer system, e.g. by its electronic control unit, operate the illumination source according to the above-mentioned protocol.
[0112] The lighting system 1 can be used to treat skin diseases or disorders, which may be or include neoplastic skin diseases such as actinic keratosis, basal cell carcinoma, in situ squamous cell carcinoma, or warts, acne, wound healing disorders / chronic wounds, bacterial and / or fungal infectious or inflammatory skin diseases. However, it is noted that it can also be used for non-therapeutic methods.
[0113] A kit for treating a disease, for example a skin disease, such as a neoplastic skin disease, may comprise a medicinal product suitable for topical administration to the skin in the area to be treated, and the above-mentioned illumination system 1, configured to illuminate the area of the skin where the substance has been administered. The medicinal product may be a photosensitizer or a precursor of a drug that can be excited by light in the emission spectrum.
[0114] A method for treating a skin disease, such as, for example, one of those described above, may comprise the following steps: administering a medicinal product, such as a prodrug as described above, to the skin of the area to be treated; illuminating said area with an illumination source 2 according to the method and / or using the illumination system 1 described above.
[0115] Applying the illumination protocol as described above is expected to not only increase efficacy but also reduce the severity of pain sensation or overall pain experienced by the patient / user. A substantial amount of perceived pain is a major problem, which masks the widespread acceptance of PDT by patients. Patients usually report experiencing a relatively high amount of pain during the illumination, ranging from mild inconvenience to severe pain that forces them to abandon treatment. This, of course, has major negative implications for individual PDT sessions and PDT treatment as a whole.
[0116] Application of the proposed photodynamic therapy lighting system reduces pain during PDT to a tolerable level, and in addition, the willingness to undergo treatment and to undergo PDT again is significantly improved with the adoption of this lighting system.
[0117] Although PDT is a highly effective treatment, recurrence of the treated disease, such as actinic keratosis and other diseases mentioned above in this disclosure, is commonplace, and thus, although successfully treated, patients often develop different lesions in different skin areas at a later date, again requiring medical intervention. Moreover, some patients are not cured completely with a single PDT session and require a second session. If the first PDT they undergo is painful, they are unlikely to complete the second PDT, despite the fact that it can provide comparable efficacy compared to other therapeutic options.
[0118] As a result, the proposed lighting system and protocol will increase the level of acceptance for photodynamic therapy.
[0119] One particular lighting system and / or associated protocols have been described. However, it should be understood that different systems and protocols may be similarly applied using the features discussed in the introduction of this disclosure, even if these features are not explicitly shown in connection with the drawings. Thus, the features discussed in the introduction are representative embodiments of the present disclosure that explicitly refer to these features. [Explanation of symbols]
[0120] 1. Lighting system 2 illumination source 3. Electromagnetic Radiation 4 Target surface 5. Electronic Control Unit p Priming mode a. First mode b. Second mode c. Third mode
Claims
1. 1. A photodynamic therapy illumination system, comprising: an illumination source configured to emit electromagnetic radiation to illuminate a target surface during operation; and an electronic control unit; the illumination source is configured to vary an intensity of electromagnetic radiation emitted by the illumination source; the electronic control unit is operably coupled to the illumination sources and configured to control operation of the illumination sources in accordance with a lighting protocol during a lighting session executed with the lighting system; and The lighting protocol includes instructions for operating the lighting source during the lighting session in a number of different modes, the modes including: a) a first mode, wherein in the first mode, the electronic control unit controls operation of the illumination source to continuously or quasi-continuously increase an intensity of electromagnetic radiation emitted by the illumination source from a base intensity B to a target intensity T within a first mode time interval; b) a second mode, where in the second mode, the electronic control unit controls operation of the illumination source to cause an intensity of electromagnetic radiation emitted by the illumination source to be constant or substantially constant during a second mode time interval; and c) a third mode, wherein in the third mode, said electronic control unit controls operation of said illumination source to alternate between periods of darkness and periods of illumination during a third mode time interval. Including, wherein the intensity of the electromagnetic radiation emitted by the illumination source is lower during a darkness period than during the illumination period, or during a darkness period, the illumination source does not emit electromagnetic radiation, while during the illumination period, the illumination source emits electromagnetic radiation.
2. 2. The lighting system of claim 1, wherein B is less than or equal to one of the following values: 0.5T, 0.45T, 0.4T, 0.35T, 0.3T.
3. 13. The illumination system of any preceding claim, wherein B is greater than or equal to one of the following values: 0.1T, 0.15T, 0.2T, 0.25T, 0.3T.
4. 13. The lighting system of any of the preceding claims, wherein the illumination source is operated in a second mode after the first mode and / or before a third mode during the lighting session.
5. 13. The lighting system of any preceding claim, wherein a beginning of operation of the illumination source in a first mode defines a start of the lighting session and an end of operation of the illumination source in a third mode defines an end of the lighting session.
6. 13. A lighting system according to any of the preceding claims, wherein every mode selected from the first, second and third modes of operation of the illumination source occurs once, preferably only once, during the lighting session.
7. 13. The illumination system of any preceding claim, wherein the electromagnetic radiation has a peak wavelength within the visible spectral range, e.g. the red, green, yellow or blue spectral range.
8. 13. The illumination system of claim 1, wherein the target surface is positioned at a target position relative to the illumination source during the illumination session, and the illumination system is configured to irradiate the target surface with a predetermined radiation dose during the illumination session.
9. The radiation dose has a value of 30 J / cm when the target surface is positioned at a target position relative to the illumination source during the illumination session. 2 , 35 J / cm 2 , 37 J / cm 2 9. The lighting system of claim 8, wherein the luminance is greater than or equal to one of:
10. The radiation dose was 45 J / cm when the target surface was positioned at a target position relative to the illumination source during the illumination session. 2 , 40 J / cm 2, 37 J / cm 2 10. The lighting system according to claim 8 or 9, wherein the luminance is smaller than or equal to one of:
11. The radiation dose has a value of 8 J / cm when the target surface is positioned at a target position relative to the illumination source during the illumination session. 2 , 9 J / cm 2 , 10 J / cm 2 11. The lighting system according to claim 8, wherein the luminance is greater than or equal to one of:
12. The radiation dose has a value of 12 J / cm when the target surface is positioned at a target position relative to the illumination source during the illumination session. 2 , 11 J / cm 2 , 10 J / cm 2 12. The lighting system according to claim 8, 10 or 11, wherein the luminance is less than or equal to one of:
13. An illumination system according to any of claims 8 to 12, wherein the distance between the radiation exit surface of the illumination source and the target position is between 1 cm and 20 cm, preferably between 5 cm and 8 cm.
14. 13. A lighting system according to any preceding claim, wherein the duration of the entire lighting session is less than or equal to one of the following values: 20 minutes, 19 minutes, 18 minutes, 17 minutes, 16 minutes, 15 minutes, 14 minutes, 13 minutes.
15. 1. A method for operating an illumination source, the illumination source being operated according to an illumination protocol during a lighting session executed on the lighting system, the illumination protocol including instructions for operating the illumination source during the lighting session in a plurality of different modes, the modes including: a) a first mode, wherein in the first mode, the illumination source is operated to continuously or quasi-continuously increase an intensity of electromagnetic radiation emitted by the illumination source from a base intensity B to a target intensity T within a first mode time interval; b) a second mode, where in the second mode, the illumination source is operated to cause an intensity of electromagnetic radiation emitted by the illumination source to be constant or substantially constant during a second mode time interval; and c) a third mode, wherein in the third mode, the illumination source is operated to alternate between periods of darkness and illumination during a third mode time interval. Including, wherein an intensity of electromagnetic radiation emitted by the illumination source is lower during a darkness period than during the illumination period, or during a darkness period the illumination source does not emit electromagnetic radiation, while during the illumination period the illumination source emits electromagnetic radiation.
16. 16. A computer program product, such as a data carrier, e.g. a non-transitory data carrier, or a data stream, which contains machine-readable instructions for operating an illumination source according to the method of claim 15, in particular when loaded into a computer system and / or when executed by the computer system, e.g. by an electronic control unit thereof.
17. A kit for treating a disease, particularly a skin disease, comprising: a pharmaceutical agent suitable for topical administration to the skin in the area to be treated, and 15. An illumination system according to any one of claims 1 to 14, wherein the illumination system is configured to illuminate an area of the skin to which the substance has been administered. Including the kit.
18. 1. A method for treating a skin disease comprising the steps of: a) administering a pharmaceutical agent to the surface of the skin in the area to be treated; b) illuminating said area with an illumination source according to the method of claim 15 and / or with an illumination system according to any of claims 1 to 14, A method comprising:
19. 19. The method of claim 18 or the kit of claim 17, wherein the pharmaceutical agent is a photosensitizer or a precursor of a drug that can be excited by radiation in the emission spectrum.
20. 19. The method according to claim 18 or the kit according to claim 17, wherein the skin disease is actinic keratosis, basal cell carcinoma, in situ squamous cell carcinoma, or neoplastic skin disease such as warts, acne, wound healing disorders / chronic wounds, bacterial and / or fungal infectious, or inflammatory skin diseases.
